Exome Asset Management LLC Acquires 23,849 Shares of Ascendis Pharma A/S (NASDAQ:ASND)

Exome Asset Management LLC grew its holdings in shares of Ascendis Pharma A/S (NASDAQ:ASND - Free Report) by 119.2% in the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 43,849 shares of the biotechnology company's stock after acquiring an additional 23,849 shares during the period. Ascendis Pharma A/S comprises about 4.4% of Exome Asset Management LLC's investment portfolio, making the stock its 2nd biggest holding. Exome Asset Management LLC owned approximately 0.07% of Ascendis Pharma A/S worth $6,547,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also modified their holdings of the business. Wilmington Savings Fund Society FSB acquired a new stake in shares of Ascendis Pharma A/S in the 3rd quarter valued at about $30,000. Groupama Asset Managment acquired a new stake in Ascendis Pharma A/S during the third quarter valued at approximately $60,000. Signaturefd LLC lifted its holdings in Ascendis Pharma A/S by 13.2% during the 3rd quarter. Signaturefd LLC now owns 686 shares of the biotechnology company's stock worth $102,000 after buying an additional 80 shares during the last quarter. Searle & CO. acquired a new position in shares of Ascendis Pharma A/S in the 2nd quarter worth approximately $205,000. Finally, Rhumbline Advisers increased its holdings in shares of Ascendis Pharma A/S by 10.3% in the 2nd quarter. Rhumbline Advisers now owns 1,533 shares of the biotechnology company's stock valued at $209,000 after acquiring an additional 143 shares during the last quarter.

Ascendis Pharma A/S Stock Down 0.6 %

NASDAQ:ASND traded down $0.77 during trading hours on Friday, reaching $129.87. 239,540 shares of the company's stock were exchanged, compared to its average volume of 448,612. The company has a market capitalization of $7.88 billion, a P/E ratio of -16.07 and a beta of 0.67. Ascendis Pharma A/S has a 12 month low of $111.09 and a 12 month high of $161.00. The business's 50-day simple moving average is $129.15 and its two-hundred day simple moving average is $132.72.

Analysts Set New Price Targets

A number of equities research analysts recently weighed in on the stock. The Goldman Sachs Group boosted their price objective on shares of Ascendis Pharma A/S from $180.00 to $200.00 and gave the company a "buy" rating in a research report on Tuesday, September 17th. Cantor Fitzgerald reaffirmed an "overweight" rating and set a $170.00 target price on shares of Ascendis Pharma A/S in a report on Friday, November 15th. JPMorgan Chase & Co. cut their price target on Ascendis Pharma A/S from $180.00 to $174.00 and set an "overweight" rating on the stock in a report on Wednesday, October 23rd. StockNews.com upgraded Ascendis Pharma A/S from a "sell" rating to a "hold" rating in a research report on Wednesday, November 20th. Finally, Oppenheimer dropped their target price on Ascendis Pharma A/S from $190.00 to $180.00 and set an "outperform" rating on the stock in a research report on Friday, November 15th. Two analysts have rated the stock with a hold rating and twelve have assigned a buy rating to the company's stock. According to data from MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and a consensus target price of $191.77.

Ascendis Pharma A/S Company Profile

Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates.